Genome mining of the deep sea-derived Streptomyces atratus SCSIO ZH16 enabled the activation of a cyclodepsipeptide gene cluster and isolation of its cinnamic acid-bearing product, atratumycin (1). Atratumycin's structure was elucidated on the basis of extensive spectroscopic experiments, X-ray data, and Marfey's method; a plausible biosynthesis and tailoring modification of 1 are also proposed and investigated. Additionally, atratumycin is active against Mycobacteria tuberculosis H37Ra and H37Rv with MICs of 3.8 and 14.6 μM, respectively.

Background:The aim of this study was to evaluate the prognostic role of neutrophil–lymphocyte ratio (NLR) in patients with acute ischemic stroke (AIS).Methods:PubMed, Embase, Web of Science, Cochrane Library, and China National Knowledge Infrastructure were searched for potential eligible literature. The study characteristics and relevant data were extracted. Odds ratios (ORs) with 95% confidence intervals (CIs) were pooled to estimate the prognostic role of NLR in patients with AIS. Poor functional outcome was defined as modified Rankin Scale ≥ 3.Results:Nine studies with 2947 patients were included. The pooled OR of higher NLR for poor functional outcome at 3 months was 1.55 (95% CI, 1.21–2.00). The pooled ORs for death at 3 months, poor functional outcome at discharge, and symptomatic intracranial hemorrhage (sICH) were 2.35 (95% CI, 0.40–13.78), 2.38 (95% CI, 0.49–11.69), and 4.32 (95% CI, 2.46–7.61), respectively.Conclusion:For patients with AIS, higher NLR was associated with poorer functional outcome at 3 months and may be associated with a higher risk of developing sICH. This readily available and inexpensive marker may be helpful in future clinical and research work. However, due to the limited number of included studies, more well-designed studies are warranted to further clarify this issue.

Destruction of tumor metabolism symbiosis is an attractive cancer treatment method which targets tumor cells with little harm to normal cells. Yet, a single intervention strategy and poor penetration of the drug in tumor tissue result in limited effect. Herein, we propose a zero‐waste zwitterion‐based hydrogen sulfide (H2S)‐driven nanomotor based on the basic principle of reaction in human body. When loaded with monocarboxylic acid transporter inhibitor α‐cyano‐4‐hydroxycinnamic acid (α‐CHCA), the nanomotor can move in tumor microenvironment and induce multiple acidosis of tumor cells and inhibit tumor growth through the synergistic effect of motion effect, driving force H2S and α‐CHCA. Given the good biosafety of the substrate and driving gas of this kind of nanomotor, as well as the limited variety of nanomotors currently available to move in the tumor microenvironment, this kind of nanomotor may provide a competitive candidate for the active drug delivery system of cancer treatment.